back-to-top

 

YOU ARE NOW
LEAVING SUSPECTANDDETECT.COM

 

Links to other sites are provided as a convenience
to the visitor. Pfizer accepts no responsibility for
the content of linked sites.

CONTINUE TO SITE
STAY HERE

RESOURCES

相關資源

These resources are provided to help health care professionals suspect and detect ATTR-CM more promptly and precisely in their patients.

SUSPECT RESOURCES

DETECT RESOURCES

SUSPECT RESOURCES

懷疑 ATTR-CM - 相關資源

REVEALING ATTR-CM IN CLINICAL PRACTICE: SEEING THE SIGNS

Presented by:

Dr. Pablo Garcia-Pavia

Heart Failure and Inherited Cardiac Diseases Units
Hospital Universitario Puerta de Hierro
Madrid, Spain

Join Dr. Garcia-Pavia as he presents an overview of ATTR-CM and highlights the clinical clues that raise suspicion of the disease. Dr. Garcia-Pavia also introduces the case of a patient with suspected ATTR-CM.

Run time: 15 minutes 26 seconds
Embed Video

Pfizer Taiwan has reviewed the content to meet the specified standards in this document but not to ensure references are correctly cited.
The views and opinions mentioned in the presentation are strictly that of the author and the individuals expressing the same and Pfizer may not necessarily endorse the same. Pfizer (including its parent, subsidiary and affiliate entities) makes no representation or warranties of any kind, expressed or implied; as to the content used in the presentation and / or the accuracy, completeness of its content.

DETECT RESOURCES

檢測 ATTR-CM - 相關資源

REVEALING ATTR-CM IN CLINICAL PRACTICE: CONFIRMING THE DIAGNOSIS

Presented by:

Dr. Pablo Garcia-Pavia

Heart Failure and Inherited Cardiac Diseases Units
Hospital Universitario Puerta de Hierro
Madrid, Spain

In this video, Dr. Garcia-Pavia reviews selected noninvasive and invasive approaches for diagnosing ATTR-CM to help clinicians put the clues together and unmask ATTR-CM in practice. Dr. Garcia-Pavia also presents a case of a patient who is diagnosed with ATTR-CM.

Run time: 16 minutes 15 seconds
Embed Video

Pfizer Taiwan has reviewed the content to meet the specified standards in this document but not to ensure references are correctly cited.
The views and opinions mentioned in the presentation are strictly that of the author and the individuals expressing the same and Pfizer may not necessarily endorse the same. Pfizer (including its parent, subsidiary and affiliate entities) makes no representation or warranties of any kind, expressed or implied; as to the content used in the presentation and / or the accuracy, completeness of its content.

DIAGNOSTIC IMAGING OF ATTR-CM WITH NUCLEAR SCINTIGRAPHY

Early diagnosis of ATTR-CM is critical, as prognosis worsens rapidly with continued amyloid deposition, subsequent advancing organ dysfunction, and significant reduction in quality of life.3,4

When ATTR-CM is suspected, diagnosis can be made noninvasively with nuclear scintigraphy and testing to rule out AL amyloidosis.1,2

Available for download soon.

NuclearScintigraphy Resource

FREE GENETIC TESTING AND COUNSELING

Pfizer and its partners, Centogene and GeneMatters, are offering anonymous genetic testing and counseling, at no cost, to eligible individuals with ATTR‑CM or at risk of developing it.* ATTR Informed

*Patient eligibility must be determined by a physician, and tests may be ordered by physicians only.

Go to ATTRINFORMED.com to learn more about this free genetic testing and counseling program

CONTENT DIRECTORY

References: 1. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. 2. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. Circ Cardiovasc Imaging. 2013;6(2):195-201. 3. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-1377. 4. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709-716.